Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maria De Santis

Showing results (201-210 of 278) with videos related to

Pageof 28
Sort By:
The Lancet. Oncology|December 15, 2023
Atezolizumab monotherapy versus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis from a randomised, controlled, phase 3 studyAristotelis Bamias, Ian D Davis, Matthew D Galsky, et al.
Frontiers in Immunology|April 16, 2014
Genome-wide analysis of DNA methylation, copy number variation, and gene expression in monozygotic twins discordant for primary biliary cirrhosisCarlo Selmi, Francesca Cavaciocchi, Ana Lleo, et al.
Nature Immunology|November 19, 2020
Macrophage expression and prognostic significance of the long pentraxin PTX3 in COVID-19Enrico Brunetta, Marco Folci, Barbara Bottazzi, et al.
Rheumatology (Oxford, England)|January 8, 2025
Gastroesophageal reflux disease is associated with a more severe interstitial lung disease in systemic sclerosis in the EUSTAR cohortEliane Roth, Cosimo Bruni, Liubov Petelytska, et al.
Cancer Immunology Research|January 24, 2025
Different PD-L1 Assays Reveal Distinct Immunobiology and Clinical Outcomes in Urothelial CancerMatthew D Galsky, Mark Kockx, Juliette Roels, et al.
Future Oncology (London, England)|April 2, 2026
How enfortumab vedotin plus pembrolizumab affects the quality of life of people with advanced urothelial cancer compared with platinum-based chemotherapy: a plain language summary of patient-reported outcomes from the EV-302 studyShilpa Gupta, Yohann Loriot, Michiel S Van der Heijden, et al.
Immunotherapy|November 11, 2020
Pasotuxizumab, a BiTE<sup>®</sup> immune therapy for castration-resistant prostate cancer: Phase I, dose-escalation study findingsHorst-Dieter Hummel, Peter Kufer, Carsten Grüllich, et al.
The Lancet. Oncology|May 31, 2025
Enfortumab vedotin plus pembrolizumab versus chemotherapy in patients with previously untreated locally advanced or metastatic urothelial cancer (EV-302): patient-reported outcomes from an open-label, randomised, controlled, phase 3 studyShilpa Gupta, Yohann Loriot, Michiel S Van der Heijden, et al.
The Lancet. Oncology|March 20, 2025
Health-related quality of life with belzutifan versus everolimus for advanced renal cell carcinoma (LITESPARK-005): patient-reported outcomes from a randomised, open-label, phase 3 trialThomas Powles, Toni K Choueiri, Laurence Albiges, et al.
The Lancet. Oncology|December 16, 2014
Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3-pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trialCora N Sternberg, Iwona Skoneczna, J Martijn Kerst, et al.
Pageof 28

Showing results (201-210 of 278) with videos related to

Sort By:
Pageof 28
The Lancet. Oncology|December 15, 2023
Atezolizumab monotherapy versus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis from a randomised, controlled, phase 3 studyAristotelis Bamias, Ian D Davis, Matthew D Galsky, et al.
Frontiers in Immunology|April 16, 2014
Genome-wide analysis of DNA methylation, copy number variation, and gene expression in monozygotic twins discordant for primary biliary cirrhosisCarlo Selmi, Francesca Cavaciocchi, Ana Lleo, et al.
Nature Immunology|November 19, 2020
Macrophage expression and prognostic significance of the long pentraxin PTX3 in COVID-19Enrico Brunetta, Marco Folci, Barbara Bottazzi, et al.
Rheumatology (Oxford, England)|January 8, 2025
Gastroesophageal reflux disease is associated with a more severe interstitial lung disease in systemic sclerosis in the EUSTAR cohortEliane Roth, Cosimo Bruni, Liubov Petelytska, et al.
Cancer Immunology Research|January 24, 2025
Different PD-L1 Assays Reveal Distinct Immunobiology and Clinical Outcomes in Urothelial CancerMatthew D Galsky, Mark Kockx, Juliette Roels, et al.
Future Oncology (London, England)|April 2, 2026
How enfortumab vedotin plus pembrolizumab affects the quality of life of people with advanced urothelial cancer compared with platinum-based chemotherapy: a plain language summary of patient-reported outcomes from the EV-302 studyShilpa Gupta, Yohann Loriot, Michiel S Van der Heijden, et al.
Immunotherapy|November 11, 2020
Pasotuxizumab, a BiTE<sup>®</sup> immune therapy for castration-resistant prostate cancer: Phase I, dose-escalation study findingsHorst-Dieter Hummel, Peter Kufer, Carsten Grüllich, et al.
The Lancet. Oncology|May 31, 2025
Enfortumab vedotin plus pembrolizumab versus chemotherapy in patients with previously untreated locally advanced or metastatic urothelial cancer (EV-302): patient-reported outcomes from an open-label, randomised, controlled, phase 3 studyShilpa Gupta, Yohann Loriot, Michiel S Van der Heijden, et al.
The Lancet. Oncology|March 20, 2025
Health-related quality of life with belzutifan versus everolimus for advanced renal cell carcinoma (LITESPARK-005): patient-reported outcomes from a randomised, open-label, phase 3 trialThomas Powles, Toni K Choueiri, Laurence Albiges, et al.
The Lancet. Oncology|December 16, 2014
Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3-pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trialCora N Sternberg, Iwona Skoneczna, J Martijn Kerst, et al.
Pageof 28